首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   185169篇
  免费   14127篇
  国内免费   4679篇
耳鼻咽喉   1115篇
儿科学   2749篇
妇产科学   1728篇
基础医学   12431篇
口腔科学   2430篇
临床医学   16396篇
内科学   18460篇
皮肤病学   1852篇
神经病学   12570篇
特种医学   3959篇
外国民族医学   8篇
外科学   12061篇
综合类   37614篇
一般理论   4篇
预防医学   17708篇
眼科学   1477篇
药学   23290篇
  432篇
中国医学   32484篇
肿瘤学   5207篇
  2023年   2938篇
  2022年   4976篇
  2021年   7321篇
  2020年   8398篇
  2019年   11138篇
  2018年   6135篇
  2017年   6744篇
  2016年   6185篇
  2015年   6038篇
  2014年   15017篇
  2013年   13683篇
  2012年   13868篇
  2011年   13837篇
  2010年   10902篇
  2009年   8656篇
  2008年   7918篇
  2007年   7858篇
  2006年   6532篇
  2005年   5349篇
  2004年   4291篇
  2003年   3700篇
  2002年   2995篇
  2001年   2614篇
  2000年   2217篇
  1999年   1670篇
  1998年   1375篇
  1997年   1318篇
  1996年   1059篇
  1995年   1063篇
  1994年   1007篇
  1993年   796篇
  1992年   741篇
  1991年   721篇
  1990年   580篇
  1989年   520篇
  1988年   514篇
  1987年   476篇
  1986年   440篇
  1985年   1238篇
  1984年   1636篇
  1983年   1199篇
  1982年   1228篇
  1981年   1170篇
  1980年   1056篇
  1979年   968篇
  1978年   840篇
  1977年   591篇
  1976年   670篇
  1975年   528篇
  1974年   497篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus.  相似文献   
3.
4.
5.
Considerable advances have been made in the research and development of oligonucleotide therapeutics (OTs) for treating central nervous system (CNS) diseases, such as psychiatric and neurodegenerative disorders, because of their promising mode of action. However, due to the tight barrier function and complex physiological structure of the CNS, the efficient delivery of OTs to target the brain has been a major challenge, and intensive efforts have been made to overcome this limitation. In this review, we summarize the representative methodologies and current knowledge of biodistribution, along with the pharmacokinetic/pharmacodynamic (PK/PD) relationship of OTs in the CNS, which are critical elements for the successful development of OTs for CNS diseases. First, quantitative bioanalysis methods and imaging-based approaches for the evaluation of OT biodistribution are summarized. Next, information available on the biodistribution profile, distribution pathways, quantitative PK/PD modeling, and simulation of OTs following intrathecal or intracerebroventricular administration are reviewed. Finally, the latest knowledge on the drug delivery systems to the brain via intranasal or systemic administration as noninvasive routes for improved patient quality of life is reviewed. The aim of this review is to enrich research on the successful development of OTs by clarifying OT distribution profiles and pathways to the target brain regions or cells, and by identifying points that need further investigation for a mechanistic approach to generate efficient OTs.  相似文献   
6.
7.
IntroductionHere, we propose a novel modified Carba NP test for detecting KPC-producing Enterobacterales using imipenem/relebactam.Material and methodsThe test performance was evaluated in a random selection of 160 previously molecularly characterized clinical isolates carrying the 110 blaKPC, 1 blaGES, 12 blaVIM, 4 blaIMP, 3 blaNDM and 42 blaOXA-48-like genes. The proposed method relies on the detection of imipenem hydrolysis in an imipenem/relebactam antibiotic solution and subsequent visual interpretation by color change.ResultsAll class A producing Enterobacterales (111/111) were detected using imipenem/relebactam as no visual appreciation of color change was perceived due to a nule hydrolysis of imipenem in the antibiotic solution. Overall, the assay showed 100% sensitivity (111/111) and specificity (69/69) for detecting class A KPC-producing Enterobacterales.DiscussionThe biochemical assay provides very reliable results for detecting KPC-producing Enterobacterales, with a turnaround time of less than 1 hour, minimum handling and no specialized equipment required.  相似文献   
8.
9.
Anticytoplasmic neutrophil antibodies (ANCA)-associated vasculitis (AAV) are rare systemic immune-mediated diseases characterized by small vessel necrotizing vasculitis and/or respiratory tract inflammation. Over the last 2 decades, anti-MPO vasculitis mouse model has enlightened the role of ANCA, neutrophils, complement activation, T helper cells (Th1, Th17) and microbial agents. In humans, CD4T cells have been extensively studied, while the dramatic efficacy of rituximab demonstrated the key role of B cells. Many areas of uncertainty remain, such as the driving force of GPA extra-vascular granulomatous inflammation and the relapse risk of anti-PR3 AAV pathogenesis. Animal models eventually led to identify complement activation as a promising therapeutic target. New investigation tools, which permit in depth immune profiling of human blood and tissues, may open a new era for the studying of AAV pathogenesis.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号